Troxipide

Cat. No.: HY-B0758 Purity: 99.45%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties.

For research use only. We do not sell to patients.

Troxipide Chemical Structure

CAS No. : 30751-05-4

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 38	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 38	In-stock	Estimated Time of Arrival: December 31
Solid
250 mg	USD 35	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 68	In-stock	Estimated Time of Arrival: December 31
1 g	USD 130	In-stock	Estimated Time of Arrival: December 31
5 g	USD 460	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Troxipide:

Troxipide (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU)^[1].
Troxipide (40 mg/kg; iv) has a T_1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal control group (NCG) and gastric ulcer group (GUG) rat (5% acetic acid 10 mL/kg/day)^[1]
Dosage:	10, 20, 40, 60 mg/kg
Administration:	Oral; daily; 2 weeks
Result:	The levels of these cytokines (IL-17, IL-6, TNF-α, IFN-γ and AP-1) were significantly reduced, suggesting that GU was significantly alleviated.

Animal Model:	NCG and GUG rat^[1]
Dosage:	40 mg/kg for iv
Administration:	IV
Result:	Had a T_1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.

Molecular Weight

294.35

Formula

C₁₅H₂₂N₂O₄

CAS No.

30751-05-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 9.09 mg/mL (30.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (3.40 mM; ultrasonic and warming and heat to 80°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3973 mL	16.9866 mL	33.9732 mL
5 mM	0.6795 mL	3.3973 mL	6.7946 mL
10 mM	0.3397 mL	1.6987 mL	3.3973 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution

This protocol yields a clear solution of ≥ 0.91 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution

This protocol yields a clear solution of ≥ 0.91 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution

This protocol yields a clear solution of ≥ 0.91 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.1 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.45%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (249 KB) LCMS (270 KB)

Handling Instructions (2659 KB)

References

[1]. Hongbin Guo, et al. Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer. Sci Rep. 2020 Aug 12;10(1):13619. [Content Brief]

[2]. K Kusugami, et al. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000 May;32(4):305-11. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	3.3973 mL	16.9866 mL	33.9732 mL	84.9329 mL
DMSO	5 mM	0.6795 mL	3.3973 mL	6.7946 mL	16.9866 mL
	10 mM	0.3397 mL	1.6987 mL	3.3973 mL	8.4933 mL
	15 mM	0.2265 mL	1.1324 mL	2.2649 mL	5.6622 mL
	20 mM	0.1699 mL	0.8493 mL	1.6987 mL	4.2466 mL
	25 mM	0.1359 mL	0.6795 mL	1.3589 mL	3.3973 mL
	30 mM	0.1132 mL	0.5662 mL	1.1324 mL	2.8311 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Troxipide Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Troxipide30751-05-4OthersorallydefensivefactorgastritisgastriculcerantiulcerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks